Pošlji prijatelju
google +
Različica za tiskanje

Novica (Droge)

This section on health in the EU has been created as a trustworthy gateway to a wide range of information and data on health-related issues and activities at both European, national and international level. The content is produced by the European Commission, the Member States of the EU and the European Economic Area (EEA), plus EU candidate countries; by international organisations; and by pan-European non-governmental organisations in the area of public health.

Just published: Wound botulism in people who inject heroin in Norway and the United Kingdom    europa.eu

The European Centre for Disease Prevention and Control (ECDC) and the EMCDDA released a joint risk assessment on wound botulism among people who inject heroin in Norway and the United Kingdom in Febr[...]

Just published: EMCDDA internal statistics code of practice    europa.eu

One of the three core principles of the EMCDDA 2013-15 strategy is a commitment to efficiency. This is to be achieved, among others, via an improved quality assurance framework for the statistical pr[...]

Just published: Work programme 2015    europa.eu

The EMCDDA's 2015 annual work programme sets out the objectives for the final year of the agency's 2013-15 strategy. Among the core principles are: delivering a relevant, timely and responsive analys[...]

New EMCDDA annual work programme published today    europa.eu

The EMCDDA has published today its 2015 annual work programme, adopted by its Management Board on 5 December. The new programme sets out the objectives for the final year of the agency's 2013-15 stra[...]

Just published: Drugnet Europe 89    europa.eu

In this issue: New EMCDDA trendspotter study explores online supply of drugs | EMCDDA scientific paper award 2015 | New review studies the effectiveness of overdose antidote, naloxone | Finland updat[...]

New EMCDDA review studies the effectiveness of overdose antidote, naloxone    europa.eu

Can naloxone provided in the community help reduce the thousands of drug-induced deaths recorded in Europe every year? This is the question explored by the EU drugs agency (EMCDDA) in a new paper rel[...]

Just published: Preventing fatal overdoses: a systematic review of the effectiveness of take-home naloxone    europa.eu

Drug overdose is one of the major causes of death among young people in Europe. This paper considers how naloxone - an effective antidote that can reverse opioid intoxication - combined with training[...]

Registration opens for fourth European drugs summer school    europa.eu

The University Institute of Lisbon (ISCTE-IUL) and the EU drugs agency (EMCDDA) will be joining forces again this summer to hold the fourth European drugs summer school (EDSS) on 'Illicit drugs in Eu[...]

Cognitive executive impairment and dopaminergic deficits in de novo Parkinson's disease    epda.eu.com

Study findings support the hypothesis that nigrostriatal dopaminergic deficit is associated with executive impairment, but not to memory or visuospatial impairment, in early PD.[...]

Frequency of Cholinergic & Caudate Nucleus Dopaminergic Deficits Across the Predemented Cognitive Spectrum of Parkinson's .....    epda.eu.com

Cortical cholinergic denervation is a major neurodegeneration associated with progressive declines across the spectrum of cognitive impairment in PD and typically occurs in the context of significant[...]

Parkinson's Disease Severity and Use of Dopaminergic Medications    epda.eu.com

The outcomes measured at the beginning of the study showed lower disease burden for participants on initial DA monotherapy compared to those taking combined LD and DA therapy after controlling for ag[...]

Effects of cannabidiol in the treatment of patients with Parkinson's disease: An exploratory double-blind trial    epda.eu.com

Study findings point to a possible effect of CBD in improving quality of life measures in PD patients with no psychiatric comorbidities; however, studies with larger samples and specific objectives a[...]

Constipation is reduced by beta-blockers and increased by dopaminergic medications in Parkinson's disease    epda.eu.com

Conclusions: Beta-blockers are associated with a lower risk of constipation, while dopaminergic treatments appear to increase risk of constipation.[...]

Cracking the code of the unspoken language    europa.eu

A Marie Curie research fellow, Oya Aran, has paved the way for the development of computer techniques that could automatically reveal meaning from body language and other visual cues, predict people'[...]

Dopaminergic medication does not improve stepping responses following backward & forward balance perturbations in Parkinson's    epda.eu.com

In conclusion, dopaminergic medication does not improve underscaling of stepping responses in PD. Therefore, other interventions are needed to improve these important defense postural reactions.[...]

Annual award ceremony to celebrate excellence in scientific writing on illicit drugs    europa.eu

The four winners of the 2014 EMCDDA scientific paper award will be honoured in Lisbon on 25 November at the fourth annual award ceremony hosted by the EU agency. The winners will receive a non-moneta[...]

Click and learn with the new-look Best practice portal from the European Monitoring Centre for Drugs and Drug Addiction    europa.eu

Targeted at practitioners and professionals, the portal is designed as a practical and reliable source of what works, and what doesn’t, in the areas of drug-related prevention, treatment, harm reduct[...]

Dopaminergic agents and nutritional status in Parkinson's disease    epda.eu.com

Results: In linear regression, total levodopa (l-dopa) equivalent daily dose (LEDD) was associated with worse MNA (B = 0.14, 95% CI = 0.26-0.02; P = 0.019). This association remained significant only[...]


The European Commission is solely responsible for information present on EU-level websites, information present in the Portal originated by the Commission. National-level information is provided by the Member States concerned and Member States are solely responsible for the accuracy of the information. Likewise, the European Commission is not responsible for information on non-governmental organisations and international organisations websites. The European Union is committed to user privacy. Read more concerning the Legal Notice.
Further questions can be answered through the Contact page. The Health-EU portal supports principles and measures to increase the credibility of information on the net. It complies with the HONcode standard for trustworthy health information: verify here.